Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK inhibitor GSK1120212 plus gemcitabine vs placebo plus gemcitabine in metastatic pancreatic cancer
2010-019578-34Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PDAC) comparing GSK1120212 plus gemcitabine with Placebo plus gemcitabine (2 arms). Primary endpoint: Overall survival. Started Sep 2010; status: completed.
02
Drugs
trametinib
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2010-019578-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019578-34.